Blog Layout
Opticology Offshoot Receives Notice of Allowance of Important Patent
May 12, 2012
Patent Issued To Tear Glucose Research, LLC.
Opticology announced today that a key US patent for one of its spin-off companies has received a Notice of Allowance from the US patent office. Opticology principal Anthony P. Cappo is primary inventor on the patent which focusses on non-invasive diagnostics via the ocular tear film. Opticology is involved in the development of a new device to measure glucose concentrations in ocular tears as a non-invasive means of determining blood glucose without drawing blood.
The spin-off company, Tear Glucose Research, LLC, has an exclusive license to the patent for glucose determination in tears. The company is developing a novel biosensor and the accompanying handheld device which promises to be a convenient and painless means to measure blood glucose in diabetics.
Opticology, Inc. has acquired a new facility in Brooklyn New York in the waterfront manufacturing district known as Redhook. The century old buildings are being renovated to include design offices and state-of-art optical laboratories for optical test, measurement, and assembly. The new space will include an area dedicated to manufacturing of optical and mechanical components as well as a prototyping shop.
The company announced today the filing of an important patent as a result of the work of its research business unit of a field-portable system for the detection of chemical and biological agents.
Opticology celebrates 20 years of successfully serving customers in optical design, engineering, and fabrication. Established in January 1999, the company has evolved as one of the leading service provider for outsourced optical engineering and design. Providing fabrication and prototype building services is an essential part of the business and important and necessary to customers in R&D and product development. Entrenched in the industry, Opticology also supplies optical and mechanical components on an OEM basis with the same level of service. Customers primarily consist of large corporations in the fields of medical device and industrial systems.
Opticology Inc. will exhibit at SPIE BiOS 2018, a biomedical optics conference preceding SPIE Photonics West. The company intends to showcase its abilities as a contract developer of medical and scientific instruments.
Opticology Inc. will exhibit at SPIE BiOS 2017, a biomedical optics conference preceding SPIE Photonics West. The company intends to showcase its abilities as a contract developer of medical and scientific instruments.
Tear Glucose Research (TGR), a spin-off company of Opticology, Inc. is named as one of 40 companies identified developing non-invasive glucose monitoring technology to replace finger-stick blood glucose meter currently used by millions who suffer from diabetes.
In an effort to continue its broad appeal to clients in various industries, Opticology, Inc. has completed registration for ITAR through the US Department of State Office of Defense Trade Controls Compliance.
Tear Glucose Research, LLC, a biotechnology company spun out of Opticology, Inc. is featured in Crain's New York Business.
Opticology, Inc. and the New York Eye & Ear Infirmary have been awarded funding for continued development of a diagnostic device for measuring glucose levels in the human tear film.
In partnership with New York Eye & Ear Infirmary and the Lighthouse International, both of New York, Opticology principals Anthony Cappo and Matthew Orr will present their findings from a clinical study entitled A New Method to Depict Central Scotomas: Automated Stereocampimetry at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle this coming May.
For over 20 years, Opticology has successfully served customers in optical design, engineering, and fabrication.
Find Us
Opticology, Inc. 99 Commerce Street, Brooklyn, NY 11231
Contact Us
212-243-4328
info@opticology.com